Brief: Abbisko Cayman Says U.S. FDA Granted Breakthrough Therapy Designation For Unit's Drug
30/01/2023 01:51
Jan 30 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* U.S. FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR
ABBISKO
THERAPEUTICS' CSF-1R INHIBITOR PIMICOTINIB
Source text for Eikon: ID:nHKS49qw3Z
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly